SCHEMBL7879859

SCHEMBL7879859

CNC(N)=NC(=O)c1cc2c(Cl)ccc(Oc3cccnc3)c2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.38
P2RX4 Q99571 1/20 0.37
MALT1 Q9UDY8 1/20 0.36
MAPT P10636 1/20 0.36
NUDT1 P36639 1/20 0.35
GRM5 P41594 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35
HTT P42858 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
BRAF P15056 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7881036 0.88 ESRRA (0.35) KDM4EBRAF
SCHEMBL7881844 0.88 RHEB (0.44) KDM4EGAA
SCHEMBL7884689 0.87 SMN1; SMN2 (0.43) SMN1; SMN2NUDT1ALDH1A1KDM4EMEN1
SCHEMBL7873840 0.87 ICAM1 (0.32) KDM4E
SCHEMBL7879425 0.85 IDO1 (0.46) SMN1; SMN2GRM5DRD2DRD3ALDH1A1
SCHEMBL7884847 0.85 RHEB (0.35) MEN1KMT2ABRAF
SCHEMBL7881933 0.84 PRMT5 (0.34) BRAF
Hydrochloric Acid SCHEMBL7877482 0.84 RHEB (0.34) MEN1KMT2ABRAF
SCHEMBL7873269 0.83 ESRRA (0.38) KDM4EBRAF
SCHEMBL7881176 0.83 MAPK14 (0.38) BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed